Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials

Eitemau Tebyg

• Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials
  gan: Foster, Nathan R., et al.
  Cyhoeddwyd: (2010)
• Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
  gan: Reungwetwattana, Thanyanan, et al.
  Cyhoeddwyd: (2012)
• Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426
  gan: Adjei, Alex A., et al.
  Cyhoeddwyd: (2010)
• A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321
  gan: Zhao, Yujie, et al.
  Cyhoeddwyd: (2015)
• A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621
  gan: Molina, Julian R., et al.
  Cyhoeddwyd: (2014)